PLB-001 / Primelink Bio - LARVOL DELTA

PLB-001, a novel anti-dll3 ADC with topoisomerase 1 inhibitor-based linker-payload for treatment of SCLC (AACR 2025) - "This ADC also exhibited potent and durable antitumor effects in cell line-derived and patient-derived xenograft models, and exhibited favorable pharmacokinetic profiles. These preclinical result support PLB-001 as a potential candidate for the treatment of DLL3-positive SCLC"

Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3